Table 6 Comparison between pretreatment METTL3-based AML regarding of BM blasts in follow-up samples from day 28 chemotherapy till the end of the 6th month of chemotherapy
BM blast count (%) | AML cases with high normalized METTL3 gene expression (n = 25) | AML cases with low normalized METTL3 gene expression (n = 15) | Significance | |
|---|---|---|---|---|
x2 | p value | |||
Assessment of early response to chemotherapy | N = 25 | N = 15 | ||
Day 28 BM blast % | ||||
CR | 2 (8.0%) | 14 (93.3%) | 28.452 | < 0.001** |
Failure of CR | 22 (88.0%) | 1 (6.7%) | ||
Died | 1 (4.0%) | 0 (0.0%) | ||
Assessment of maintenance of CR | N = 23 | N = 13 | ||
2nd month BM blast % | ||||
≤ 5% | 13 (56.5%) | 13 (100%) | – | 0.01* |
> 5% | 8 (34.7%) | 0 (0.0%) | ||
Died | 2 (8.7%) | 0 (0.0%) | ||
N = 14 | N = 15 | |||
4th month BM blast % | ||||
≤ 5% | 8 (57.1%) | 14 (93.3%) | 5.18 | 0.023* |
> 5% | 6 (42.9%) | 1 (6.7%) | ||
N = 14 | N = 15 | |||
6th month BM blast% | ||||
≤ 5% | 6 (42.9%) | 14 (93.3%) | 8.62 | 0.003* |
> 5% | 8 (57.1%) | 1 (6.7%) | ||